Richard Duke
President,
TrAMPoline Pharma, Inc.
United States
Dr. Duke has more than 25 years of biotech experience with infectious disease vaccines, vaccine platforms, oncology drugs and immunotherapeutics. He is a biotechnology executive, inventor, biomedical researcher, and serial entrepreneur with extensive experience in building, financing, and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions. He currently serves as President of TrAMPoline Pharma, Inc and as Chairman of two other clinical stage companies namely MenoGeniX, Inc. and Aurora Oncology, Inc. He also holds several positions at the University of Colorado Anschutz Medical Campus (UC-AMC) including Professor of Medicine, Grohne Chair of Clinical Cancer Research, and Deputy AD of Commercialization of the University of Colorado Cancer Center. He was also a Co-scientific Founder and former CEO, President and Director of GlobeImmune, Inc. (NASD:GBIM), an immunotherapy and vaccine company that was acquired by NantCell, Inc. and has been involved in the formation and operations of ApopLogic Pharmaceuticals, Vona Oncology, and Rock Immune (oncology and immuno-oncology), PeptiVir (viral vaccines), and AMP Discovery (antibiotics). These spin-out companies and MenoGeniX have raised more than $250 million in financing and have advanced multiple products into phase 1 and 2 human clinical trials. He has personally prepared 4 IND applications.
Suffix
Not Applicable
Sessions
-
10-Feb-2025TrAMPoline Pharma Inc
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}